Canaccord Genuity analyst William J. Plovanic lowered the price target on DexCom (NASDAQ: DXCM) to $89.00 (from $145.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

DexCom (DXCM) PT Lowered to $145 at RBC CapitalJuly 26, 2024 6:34 AM Baird Downgrades DexCom (DXCM) to NeutralJuly 26, 2024 6:18 AM DexCom (DXCM) PT Lowered to $95 at UBSJuly 26, 2024 5:57 AM JPMorgan Downgrades DexCom (DXCM) to NeutralJuly 26, 2024 3:48 AM Dexcom shares plunge after it cuts annual revenue forecastJuly 25, 2024 6:12 PM Form 10-Q DEXCOM INC For: Jun 30July 25, 2024 5:19 PM Dexcom cuts guidance as Q2 revenue falls short of estimates; shares slumpJuly 25, 2024 4:46 PM After-hours movers: DexCom, Skechers, Deckers Brands, and moreJuly 25, 2024 4:45 PM Form 8-K DEXCOM INC For: Jul 25July 25, 2024 4:06 PM DexCom (DXCM) Tops Q2 EPS by 4c; updates guidanceJuly 25, 2024 4:05 PM DexCom (DXCM) Reports Q2, Updates Guidance, Announces $750M Share BuybackJuly 25, 2024 4:03 PM Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase ProgramJuly 25, 2024 4:03 PM